253 related articles for article (PubMed ID: 11960598)
41. Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Adema AD; van der Born K; Honeywell RJ; Peters GJ
J Chemother; 2009 Jun; 21(3):338-46. PubMed ID: 19567356
[TBL] [Abstract][Full Text] [Related]
42. Involvement of the mismatch repair system in temozolomide-induced apoptosis.
D'Atri S; Tentori L; Lacal PM; Graziani G; Pagani E; Benincasa E; Zambruno G; Bonmassar E; Jiricny J
Mol Pharmacol; 1998 Aug; 54(2):334-41. PubMed ID: 9687575
[TBL] [Abstract][Full Text] [Related]
43. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
Shi L; Chen J; Yang J; Pan T; Zhang S; Wang Z
Brain Res; 2010 Sep; 1352():255-64. PubMed ID: 20633539
[TBL] [Abstract][Full Text] [Related]
44. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.
Chen CC; Taniguchi T; D'Andrea A
J Mol Med (Berl); 2007 May; 85(5):497-509. PubMed ID: 17221219
[TBL] [Abstract][Full Text] [Related]
45. Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma.
Gratas C; Séry Q; Rabé M; Oliver L; Vallette FM
Oncotarget; 2014 May; 5(9):2428-35. PubMed ID: 24811082
[TBL] [Abstract][Full Text] [Related]
46. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
47. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells.
Qiu ZK; Shen D; Chen YS; Yang QY; Guo CC; Feng BH; Chen ZP
Chin J Cancer; 2014 Feb; 33(2):115-22. PubMed ID: 23958055
[TBL] [Abstract][Full Text] [Related]
48. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
49. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
50. The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.
Hayashi T; Adachi K; Ohba S; Hirose Y
J Neurooncol; 2013 Nov; 115(2):169-78. PubMed ID: 23943501
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
52. Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
Wagner LM; McLendon RE; Yoon KJ; Weiss BD; Billups CA; Danks MK
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5418-25. PubMed ID: 17875772
[TBL] [Abstract][Full Text] [Related]
53. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
54. N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.
Tang JB; Svilar D; Trivedi RN; Wang XH; Goellner EM; Moore B; Hamilton RL; Banze LA; Brown AR; Sobol RW
Neuro Oncol; 2011 May; 13(5):471-86. PubMed ID: 21377995
[TBL] [Abstract][Full Text] [Related]
55. Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Pezen DS; Dolan ME; Baron J; Yarosh DB; Foss F; Kuzel TM
Clin Cancer Res; 2011 Sep; 17(17):5748-54. PubMed ID: 21747120
[TBL] [Abstract][Full Text] [Related]
56. Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines.
Balzarotti M; Ciusani E; Calatozzolo C; Croci D; Boiardi A; Salmaggi A
Oncol Res; 2004; 14(7-8):325-30. PubMed ID: 15301423
[TBL] [Abstract][Full Text] [Related]
57. Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.
Zhu D; Tu M; Zeng B; Cai L; Zheng W; Su Z; Yu Z
Cancer Med; 2017 Feb; 6(2):452-462. PubMed ID: 28064447
[TBL] [Abstract][Full Text] [Related]
58. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Wang J; Zhou F; Li Y; Li Q; Wu Z; Yu L; Yuan F; Liu J; Tian Y; Cao Y; Zhao Y; Zheng Y
Cell Cycle; 2017; 16(24):2355-2365. PubMed ID: 29108461
[TBL] [Abstract][Full Text] [Related]
59. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis.
Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S
Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235
[TBL] [Abstract][Full Text] [Related]
60. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
Chen L; Han L; Shi Z; Zhang K; Liu Y; Zheng Y; Jiang T; Pu P; Jiang C; Kang C
Mol Med Rep; 2012 Feb; 5(2):575-9. PubMed ID: 22086271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
